vimarsana.com
Home
Live Updates
GENFIT Further Strengthens its ACLF Franchise with a Third C
GENFIT Further Strengthens its ACLF Franchise with a Third C
GENFIT Further Strengthens its ACLF Franchise with a Third Clinical-Stage Asset
Exclusive worldwide rights licensed from Seal Rock Therapeutics for injectable formulation of ASK1 Inhibitor SRT-015 in acute liver diseasePreclinical and clinical evidence support ASK1 inhibition as... | May 31, 2023
Related Keywords
Massachusetts ,
United States ,
Cambridge ,
Cambridgeshire ,
United Kingdom ,
Seal Rock ,
Paris ,
France General ,
France ,
Switzerland ,
Pascal Prigent ,
Chronic Liver Failure Consortium ,
Uncertainties Of The Company ,
Nasdaq ,
Exchange Commission ,
Drug Administration ,
Euronext ,
European University Hospitals ,
Seal Rock Therapeutics ,
Acute On Chronic Liver Failure ,
Reactive Oxygen Species ,
Investigational New Drug ,
Orphan Drug Designation ,
Chronic Liver Failure ,
Nasdaq Global Select Market ,
Rock Therapeutics ,
Private Securities Litigation Reform Act ,
Registration Document ,
Molecular Medicine ,
Genfit Stock Exchange ,
News ,
Information ,
Press Release ,
Exclusive ,
Orldwide ,
Tights ,
Icensed ,
Rom ,
Meal ,
Clock ,
Herapeutics ,
Or ,
Injectable ,
Formulation ,
F ,
Csk1 ,
Inhibitor ,
N ,
Cute ,
Liver ,
Iseasepreclinical ,
End ,
Linical ,
Evidence ,
Support ,
Nhibition Gnft Fr0004163111 ,